GenVec Announces Research on Improved Vaccine Vectors
GAITHERSBURG, Md., April 6, 2012 /PRNewswire via COMTEX/ -- GenVec, Inc. (GNVC)
announced publication of research on GenVec's new vaccine vectors. These vectors
circumvent neutralizing antibodies in order to generate the desired immunologic
response. The paper has been published online in PloS ONE, and can be accessed at
dx.plos.org. The article titled "Modification
of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing Ad5 Neutralizing
Antibodies and Induces Protective Immune Responses" is an example of GenVec's
proprietary vaccine technology.
"This paper describes one of several new tools we are using to generate better
vaccines," noted Douglas E. Brough, Ph.D., GenVec's Vice President of Research.
"This approach alters key elements of the vector so that a good vaccine response
is generated even if an individual was previously exposed to an adenovirus. This
technology expands our genetic vaccine toolbox used to create superior vaccines."
About GenVec
GenVec is a biopharmaceutical company using differentiated, proprietary
technologies to create superior therapeutics and vaccines. A key component of our
strategy is to develop and commercialize our product candidates through
collaborations. GenVec is working with leading companies and organizations such
as Novartis, Merial, and the U.S. Government to support a portfolio of product
programs that address the prevention and treatment of a number of significant
human and animal health concerns. GenVec's development programs address
therapeutic areas such as hearing loss and balance disorders; as well as vaccines
against infectious diseases including respiratory syncytial virus (RSV), herpes
simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus
(HIV). In the area of animal health we are developing vaccines against
foot-and-mouth disease (FMD). Additional information about GenVec is available at
genvec.com and in the Company's various filings with the Securities
and Exchange Commission. |
